CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in combination with lazertinib (Leclaza) not only reduces administration times but also may offer […]

Nearly 2 years after their final transfusion with the IGF-IR inhibitor teprotumumab (Tepezza), 82% of patients with thyroid eye disease did not need further treatment for […]

Insurance companies frequently deny insurance coverage of glucagon-like peptide-1 (GLP-1) receptor agonists for adolescents, according to a new analysis.  For those whose GLP-1 prescriptions were covered, […]

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase […]

The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Ozempic, Wegovy) enhances taste sensitivity, changes brain responses to sweet tastes, and may even alter expression of genes in […]

Two common cost-containment strategies — high-deductible health plans and stringent prior authorization requirements — can significantly hinder the survival and well-being of patients with cancer, according […]

CHICAGO — The benefit observed with lorlatinib (Lorbrena) in 5-year follow-up data from the CROWN trial corresponds to the longest progression-free survival (PFS) reported for any […]

A conversational artificial intelligence patient navigator was successful at re-engaging patients in colonoscopy screening, essentially doubling the colonoscopy completion rate in patients from underserved communities who […]

BOSTON — An investigative small-diameter defibrillation lead for implantable cardioverter-defibrillators has exceeded its safety and efficacy expectations in a pivotal clinical trial. The LEADR trial implanted […]